GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Intranasal glucagon

Company
University Health Network, Toronto
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT01959334

    Evaluate the Immunogenicity of a Novel Glucagon Formulation

    Not yet reported Eli Lilly and Company 75 participants Est. completion 2013-12 1 site
    Other conditions: Drug-specific Antibodies, Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT01997411

    Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes

    Not yet reported, Not yet reported Eli Lilly and Company 48 participants Est. completion 2015-01 7 sites
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT02171130

    Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia

    Not yet reported Eli Lilly and Company 129 participants Est. completion 2015-08 9 sites
    Other conditions: Hypoglycemia, Diabetes Mellitus, Drug-Specific Antibodies
    View official trial listing →
  • Completed NCT NCT02740829

    Assessment of Intranasal Glucagon on Endogenous Glucose Production

    Not yet reported University Health Network, Toronto 10 participants Est. completion 2016-03 Stand-alone
    Other conditions: Diabetes
    View official trial listing →
  • Status unknown NCT NCT03650582

    Intranasal Glucagon and Energy Balance

    Not yet reported, Not yet reported University Health Network, Toronto 20 participants Est. completion 2018-10-30 1 site Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT05206149

    Stimulation Test With Intranasal Glucagon for Corticotroph, Somatotroph and Antidiuretic Axes

    Not yet reported A.O.U. Città della Salute e della Scienza 10 participants Est. completion 2021-12-31 1 site Stand-alone
    Other conditions: Hypopituitarism
    View official trial listing →
  • Completed NCT NCT05395000

    Comparison of Ease of Use and Acceptability of Intranasal and Injectable Glucagon Among Providers Administering it to Children or Adolescents With Type 1 Diabetes (BETTER-ING)

    Not yet reported CHU de Quebec-Universite Laval 60 participants Est. completion 2022-09-22 1 site Stand-alone
    Other conditions: Diabetes Mellitus, Type 1, Hypoglycemia
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.